SAN FRANCISCO, Nov. 16, 2011 /PRNewswire/ -- Vista Partners
announced today that it has updated coverage on Cellmid Ltd. (ASX:
CDY) (the "Company") and raised its twelve month target price to
AUD $0.12. Ross Silver, Principal Analyst at Vista Partners
stated, "Cellmid is on track to enter clinical trials for its AMI
indication with a market estimated to be in the billions. The
Company recently completed humanisation of its "first in class"
anti-midkine antibody, hu91, in collaboration with Antitope Ltd.
The humanisation has been completed on time and within budget and
resulted in a drug that can enter clinical development. This is the
most significant milestone to date in the Company's antibody
program and has removed a substantial risk from the clinical
development path." Mr. Silver continued, "Cellmid has a large
portfolio of patents surrounding midkine and owns 21 patent
families worldwide. Cellmid plans to monetize this portfolio
through two segments: Diagnostics and Therapeutics. The Diagnostic
programs are in a more advanced stage and are poised to face
regulatory approvals first. The Therapeutic programs are in
pre-clinical trials; however they involve high value antibody
candidates with early partner/licensing potential."
To download a FREE copy of the Cellmid Ltd. research report,
please visit www.vistapglobal.com and complete the research form to
gain access to the report.
About Vista Partners:
Vista Partners LLC, founded in 2005, is a Registered Investment
Advisor in the States of California and Oregon. The firm's professional staff has
backgrounds in finance, corporate communications and investment
banking. Vista Partners LLC has built a name for itself in the
small cap space due to its selection of profitable investment
ideas.
Disclaimer & Disclosure:
For a full list of disclaimers and disclosures, please visit our
website www.vistapglobal.com or click here.
Contact:
877.215.4813 or info@vistapglobal.com
SOURCE Vista Partners
